Clinical, imaging, and blood biomarkers to assess 1-year progression risk in fibrotic interstitial lung diseases—Development and validation of the honeycombing, traction bronchiectasis, and monocyte (HTM)-score

INTRODUCTION: Progression of fibrotic interstitial lung disease (ILD) leads to irreversible loss of lung function and increased mortality. Based on an institutional ILD registry, we aimed to evaluate biomarkers derived from baseline patient characteristics, computed tomography (CT), and peripheral b...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Guangyu, Hawle, Patricia, Akbari, Kaveh, Horner, Andreas, Hintenberger, Rainer, Kaiser, Bernhard, Lamprecht, Bernd, Lang, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709148/
https://www.ncbi.nlm.nih.gov/pubmed/36465895
http://dx.doi.org/10.3389/fmed.2022.1043720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709148/
https://www.ncbi.nlm.nih.gov/pubmed/36465895
http://dx.doi.org/10.3389/fmed.2022.1043720

Ejemplares similares